|
**Overview**: Germ Cell Tumor Panel**Introduction**: The Germ Cell Tumor Panel is a diagnostic tool designed to screen for germ cell tumors using serum samples. In India, germ cell tumors (testicular in males, ovarian in females) account for ~2-5 percent of cancers in young adults, with AFP, beta-hCG, and LDH as key markers for diagnosis, staging, and monitoring. High morbidity from under-testing in rural/low-SES young patients with testicular/ovarian masses, limited oncology labs, delayed chemotherapy leading to metastasis or infertility. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs immunoassay for AFP, beta-hCG, LDH over 1-2 days with high sensitivity/specificity, valuable for tumor marker screening in suspected cases. This diagnostic falls under tumor marker screening and targets young adults with gonadal masses or extragonadal symptoms, addressing accurate detection to guide orchiectomy, chemotherapy, or surveillance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise marker assessment and improving survival. Its serum-based approach ensures reliable tumor marker detection.**Other Names**: Germ Cell Pnl.**FDA Status**: FDA approved, CLIA certified for oncology/immunology, compliant with 2025 standards.**Historical Milestone**: AFP/beta-hCG/LDH standard; in India, used in oncology clinics.**Purpose**: The test assesses 3 parameters including AFP to guide germ cell tumor screening, detect markers, inform staging/therapy.**Test Parameters**: 1. AFP, 2. Beta-hCG, 3. LDH.**Pretest Condition**: No fasting required; patients should report gonadal mass or symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on mass, pain, fertility issues.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated germ cell tumor including metastasis, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or non-germ cell tumors can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated markers indicate germ cell tumor, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Medical oncologists should be consulted for management.**Additional Supporting Tests**: Ultrasound, biopsy for confirmation.**Test Limitations**: Markers nonspecific; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Germ Cell Studies India 2023. |
